ABSTRACT
Objective:To evaluate the efficacy of self-made Wenyang-Huoxue Decoction combined with gestrinone capsule in the treatment of adenomyosis dysmenorrhea. Methods:A total of 88 patients with adenomyosis dysmenorrhea who met the inclusion criteria in Datong Traditional Chinese Medicine Hospital from January 2016 to December 2018 were enrolled and divided into two groups according to random number table method, 44 cases in each group. The control group was treated with conventional western medicine and the study group was treated with self-made Wenyang-Huoxue Decoction on the basis of the control group. Two groups were treated continuously for 6 months. The TCM syndrome score and dysmenorrhea score were performed before and after treatment. The vaginal ultrasound was used to detect and calculate uterine volume, Nottingham Health Poofite (NHP) was used to evaluate the quality of life. The ELISA was used to detect serum carbohydrate antigen 125 (CA125), TNF-α and IL-8 levels. The clinical efficacy was evaluated. Results:The total effective rate of the study group was 93.2% (41/44) and that of the control group was 72.7% (32/44), where the difference between the two groups was statistically significant ( χ2=6.510, P<0.01). After treatment, the TCM syndrome score, dysmenorrhea score and uterine volume of the study group were significantly lower than those in the control group ( t values were 7.956, 4.959 and 4.235, respectively, all Ps<0.01); the scores of pain, energy, emotion, sleep, social activity and physical activity were significantly lower than those in the control group ( t values were 8.592, 9.341, 6.652, 13.597, 4.085, 7.858, respectively, all Ps<0.01). After treatment, serum CA125 (33.02 ± 5.11 IU/ml vs. 46.22 ± 6.51 IU/ml, t=10.580), TNF-α (41.13 ± 5.03 pg/ml vs. 55.50 ± 6.15 pg/ml, t=11.997) and IL-8 (38.02 ± 5.50 pg/ml vs. 49.42 ± 6.51 pg/ml, t=8.873) in the study group were significantly lower than those in the control group ( P<0.01). Conclusions:Self-made Wenyang-Huoxue Decoction combined with gestrinone capsule can reduce the levels of serum CA125, TNF-α and IL-8 in patients with adenomyosis dysmenorrhea, and improve the clinical symptoms, and the quality of life.